Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
adverse drug reaction
anticonvulsants
anticonvulsants, absorption
anticonvulsants, bioavailability
anticonvulsants, blood level determination of
anticonvulsants, brand name
anticonvulsants, compliance
anticonvulsants, effectiveness
anticonvulsants, generic
anticonvulsants, pharmacokinetics
anticonvulsants, selection of
anticonvulsants, teratogenicity of
anticonvulsants, untoward effects of
behavioral disorder
brand name drug
carbamazepine
carbamazepine, toxicity
chest pain
children
complications
contraindications
controversies in neurology
cost
cost effectiveness
diabetes insipidus
dilantin
dilantin, serum level
drug interactions
drug of choice
efficacy
enzyme, induction
erythema multiforme
ethics in neurology
flushing
generic drugs
hospital length of stay
hospitalization
iatrogenic neurologic disorders
lamotrigine
manic-depressive
medical-legal aspects of neurology
migraine
migraine, treatment of
movement disorder
movement disorder, treatment of
mylan
mysoline
neck pain
pain
pain, central
pain, management of chronic
paresthesias
personality disorder
phantom limb
phenobarbital
practice guidelines
pregnancy, neurologic complications in
quality of care
quality of life
rash
recurrent
review article
risk factors
safety
seizure
seizure, breakthrough
seizure, recurrent
seizure, treatment of
sodium valproate
sumatriptan
teratogenesis
teratogenic drugs
topiramate
trauma
treatment of neurologic disorder
trigeminal neuralgia
trigeminal neuralgia, treatment of
triptans
Showing articles 0 to 50 of 1494 Next >>

Switching the Manufacturer of Antiepileptic Drugs is Associated with Higher Risk of Seizures: A Nationwide Study of Prescription Data in Germany
Ann Neurol 84:918-925, Lang, J.D.,et al, 2018

Antiseizure Medications
Neurol 86:e187-e188, Karceski, S., 2016

Assessing Bioequivalence of Generic Antiepilepsy Drugs
Ann Neurol 70:221-228,192, Krauss, G.L.,et al, 2011

Triptan Therapy in Migraine
NEJM 363:63-70, Loder,E., 2010

Generic Antiepileptic Drugs and Associated Medical Resource Utilization in the United States
Neurol 74:1566-1574, 1562, Labiner,D.M., et al, 2010

The Value of Specifying Brand-Name Antiepileptic Drugs
Arch Neurol 66:1415-1416, 1418, Ng,Y., 2009

Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Arch Neurol 66:1417-1418, Hamiwka,L., 2009

The Risks and Costs of Multiple-Generic Substitution of Topiramate
Neurol 72:2122-2129, Duh,M.S.,et al, 2009

Clinical Consequences of Generic Substitution of Lamotrigine for Patients with Epilepsy
Neurol 70:2179-2186, LeLorier,J.,et al, 2008

Generic Substitution in the Treatment of Epilepsy: Case Evidence of Breakthrough Seizures
Neurol 71:525-530, Berg,M.J.,et al., 2008

Position Statement on the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy
Neurol 68:1249-1250,1245, Liow,K.,et al, 2007

Lower Phenytoin Serum Levels in Persons Switched from Brand to Generic Phenytoin
Neurol 63:1494-1496, Burkhardt,R.T.,et al, 2004

Effect of Food on Absorption of Dilantin Kapseals and Mylan Extended Phenytoin Sodium Capsules
Neurol 57 582-589,571, Wilder,B.J.,et al, 2001

Carbamazepine Toxicity Resulting from Generic Substitution
Neurol 43:2696-2697, 24351993., Gilman,J.T.,et al, 1993

Therapeutic Bioequivalency Study of Brand Name Versus Generic Carbamazepine
Neurol 42:1147-1153, Oles,K.S.,et al, 1992

Assessment:Generic Substitution for Antiepileptic Medication
Report of Therap & Tech Assess Subcomm, Neurol 40:1641-164390., , 1990

Generic Substitutions for Antiepileptic Drugs
Neurol 40:1647-1651, Nuwer,M.R.,et al, 1990

New Uses and Old for Carbamazepine
Patient Care 24:48-81, Browne,T.R.,et al, 1990

Generic Carbamazepine and Erythema Multiforme:Generic-Drug Nonequivalency
NEJM 321:692-693, Busch,R.L., 1989

Increased Seizure Frequency with Generic Primidone
JAMA 258:1216-1217, Wyllie,E.,et al, 1987

Breakthrough Seizure Following Substitution of Depakene Capsules with a Generic Product
Neurol 37:1885, MacDonald,J.T., 1987

Migraine
NEJM 377:553-561, Charles, A., 2017

A 54-Year-Old Woman with Progressive Headache and Neurologic Decline
Neurol 102:e209190, Cheng,Y. & Zachariah,J., 2024

Forensic Neurology:Practice Considerations and Training Opportunities
Neurol 103:e209560, Zheng,D.,et al, 2024

Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated with Attendance
JAMA Neurol 81:732-740, Li,Y., et al, 2024

Brain Calcification in a Young Woman With Seizures, Explore the Rare Differentials
Neurol 100:397-398, Menon,B.,et al, 2023

Salt and Pepper Sign, PLNTY for Drug-Resistant Epilepsy
Neurol 100:791-795, Paredes-Aragon,E.M.,et al, 2023

Neonatal Seizures
NEJM 388:1692-1700, Ropper.A.H., 2023

Drug Resistant Epilepsy in a 61-Year-Old Man with Abnormal MRI Brain Findings and Management with Vagal Nerve Stimulator
Neurol 100:1111-1116, Mankad,J.P. & Lavingia,J.R., 2023

NSAIDS, Hormonal Contraception, and Venous Thromboembolism, A Harmful Drug Interaction That Deserves More Attention
BMJ 382:p1990, Schmidt,M., 2023

Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023

Study Finds ChatGPT Provides Inaccurate Responses to Drug Questions-Press Release
Am Soc Health Sys Pharm, Dec 5, Grossman,S., 2023

Severe Vitamin B12 Deficiency Presenting as Pancytpenia, Hemolytic Anemia, and Parasthesia:Could Your B12 Be Any Lower?
Cureus doi:10.7759/cureus 29225, Pelling,M.M., et al, 2022

Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary
Neurol 98:31-43, Price, R.,et al, 2022

Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022

An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022

The SANAD II study of the Effectiveness and Cost-Effectiveness of Levetiracetam, Zonisamide, or Lamotrigine for Newly Diagnosed Focal Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial
Lancet 397:1363-1374, Marson, A.,et al, 2021

The SANAD II Study of the Effectiveness and Cost-Effectiveness of Valproate Versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial
Lancet 397:1375-1386, Marson, A.,et al, 2021

Vagus Nerve Stimulation and Seizure Outcomes in Pediatric Refractory Epilepsy
Neurol 96:1041-1051, Jain, P. & Arya, R., 2021

Initial Management of Seizure in Adults
NEJM 385:251-263, Smith, P.E.M., 2021

Safety and Efficacy of Coma Induction Following First-Line Treatment in Status Epilepticus
Neurol 97:e564-e576, DeStefano, P.,et al, 2021

Clinicopathologic Conference, Seizure from Neurocysticercosis
NEJM 385:1894-1902, Case 34-2021, 2021

Antiseizure Medication Withdrawal in Seizure-Free Patients: Practice Advisory Update Summary
Neurol 97:1072-1081, Gloss, D.,et al, 2021

Efficacy and Safety of Adjunctive Lacosamide in the Treatment of Primary Generalised Tonic-Clonic Seizures: A Double-Blind, Randomised, Placebo-Controlled Trial
JNNP 91:1067-1075, Vossler, D.G.,et al, 2020

Epilepsy in Older People
Lancet 395:735-748, Sen, A.,et al, 2020

Prevalence of Cannabis Withdrawal Symptoms Among People with Regular or Dependent Use of Cannabinoids
JAMA doi:10.1001/JAMANETWORKOPEN.2020.2370, Bahji, A.,et al, 2020

Deprescribing in Epilepsy
JAMA Neurol 77:673-674, Terman, S.W.,et al, 2020

Choosing Anticonvulsant Medications to Manage Status Epilepticus
NEJM 382:2569-2572, Wu, K., 2020

FDA Approves Fenfluramine for Treatment of Seizures Associated with Dravet Syndrome
FDA June2020, , 2020



Showing articles 0 to 50 of 1494 Next >>